AACR D3: The ‘Global One-stop Conference’ for Drug Discovery and Development
The inaugural AACR Drug Discovery and Development (AACR D3) meeting will convene experts to reshape the future of oncology...
Category: Meetings
The inaugural AACR Drug Discovery and Development (AACR D3) meeting will convene experts to reshape the future of oncology...
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting...
At the AACR Annual Meeting 2026, National Cancer Institute Director Anthony Letai offered insights into what NCI considers to...
Patient advocates from the AACR Scientist↔Survivor Program shared their research on cancer during the AACR Annual Meeting 2026.
A recap of the last day of the AACR Annual Meeting 2026, including plenaries on innovative treatment modalities and...
Injecting immunotherapy directly into precancerous oral lesions may be an effective way to prevent progression to cancer without surgery.
A recap from the fifth day of the AACR Annual Meeting 2026, including a plenary on early-onset cancers, clinical...
People with alveolar soft part sarcoma can receive immunotherapy treatment for an extended period without long-term side effects.
A recap of the fourth day of the AACR Annual Meeting 2026, including a plenary on AI, the NCI...